HealthEquity, Inc. (NASDAQ:HQY) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analysts remain broadly bullish: HealthEquity has a “Moderate Buy” consensus from 13 analysts, with an average 12-month price target of $112.20 versus a recent price of $94.52.
• Recent results exceeded expectations: The company reported quarterly EPS of $1.24, beating estimates by $0.05, while revenue reached $350.73 million and increased 95.5% year over year.
• Ownership and trading activity: Insiders sold 12,456 shares worth about $1.26 million over the past three months, while institutional investors collectively own 99.55% of the company.

Shares of HealthEquity, Inc. (NASDAQ:HQY - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the thirteen ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $112.20.

HQY has been the topic of several recent analyst reports. Wells Fargo & Company set a $111.00 target price on HealthEquity in a report on Monday, June 1st. Royal Bank Of Canada lifted their price target on HealthEquity from $100.00 to $108.00 and gave the company an "outperform" rating in a research report on Wednesday, June 3rd. Citigroup reaffirmed a "market outperform" rating on shares of HealthEquity in a research note on Friday, August 28th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of HealthEquity from $135.00 to $142.00 and gave the stock a "buy" rating in a research report on Monday, August 31st. Finally, Raymond James Financial restated a "strong-buy" rating on shares of HealthEquity in a research report on Thursday, September 3rd.

HealthEquity Trading Down 0.7%

Shares of HQY stock opened at $94.52 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.99 and a current ratio of 2.99. HealthEquity has a 1 year low of $72.76 and a 1 year high of $107.62. The stock has a fifty day moving average of $99.59 and a two-hundred day moving average of $90.10. The firm has a market capitalization of $7.82 billion, a PE ratio of 34.12, a price-to-earnings-growth ratio of 1.50 and a beta of 0.22.

HealthEquity (NASDAQ:HQY - Get Free Report) last released its earnings results on Thursday, August 27th. The company reported $1.24 EPS for the quarter, beating the consensus estimate of $1.19 by $0.05. The firm had revenue of $350.73 million for the quarter, compared to analysts' expectations of $349.22 million. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The business's revenue was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. As a group, research analysts expect that HealthEquity will post 3.93 EPS for the current year.

Insider Activity at HealthEquity

In related news, EVP Michael Fiore sold 2,354 shares of HealthEquity stock in a transaction on Friday, July 10th. The stock was sold at an average price of $95.00, for a total value of $223,630.00. Following the transaction, the executive vice president directly owned 52,244 shares in the company, valued at $4,963,180. The trade was a 4.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian T. Dillon sold 7,632 shares of the business's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total value of $798,383.52. Following the sale, the director directly owned 62,395 shares in the company, valued at $6,527,140.95. This trade represents a 10.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 12,456 shares of company stock valued at $1,256,664. Company insiders own 1.60% of the company's stock.

Hedge Funds Weigh In On HealthEquity

Institutional investors have recently bought and sold shares of the stock. Leonteq Securities AG lifted its stake in HealthEquity by 159.9% during the first quarter. Leonteq Securities AG now owns 382 shares of the company's stock valued at $32,000 after buying an additional 235 shares in the last quarter. Silvant Capital Management LLC purchased a new position in shares of HealthEquity in the second quarter worth approximately $35,000. Axiom Investment Management LLC purchased a new position in shares of HealthEquity in the first quarter worth approximately $33,000. Public Employees Retirement System of Ohio acquired a new stake in shares of HealthEquity during the second quarter valued at approximately $39,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in shares of HealthEquity by 2,476.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 438 shares of the company's stock valued at $40,000 after acquiring an additional 421 shares during the period. Hedge funds and other institutional investors own 99.55% of the company's stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services for consumer-directed benefits and healthcare savings accounts. The company helps employers, benefits advisors and individuals manage tax-advantaged accounts, including health savings accounts (HSAs), flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), commuter benefits and other employee benefit programs.

Its offerings include account administration, payment cards, reimbursement services, benefits communication, compliance support, healthcare spending tools and investment options for eligible HSA funds.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.